Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
Discontinued
Reference number: GID-TA10495
Following on from information provided to NICE by the company in February 2021, the appraisal of Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.